Acadia Pharmaceuticals (ACAD) Income from Continuing Operations (2010 - 2026)
Acadia Pharmaceuticals' (ACAD) quarterly Income from Continuing Operations came in at 3681000.0 in Q1 2026, down 80.63% year-on-year from 19008000.0 in Q1 2025, and down 92.05% quarter-over-quarter from 46323000.0 in Q4 2025.
Acadia Pharmaceuticals (ACAD) Income from Continuing Operations (2010 - 2026) Analysis & Trends
Acadia Pharmaceuticals' Income from Continuing Operations history runs 17 years deep, the most recent figure standing at 3681000.0 for Q1 2026.
- On a quarterly basis, Income from Continuing Operations fell 80.63% year-over-year to 3681000.0 in Q1 2026; TTM through Mar 2026 was 148438000.0, a 41.69% decrease from a year earlier, with the FY2025 full-year figure at 163723000.0, down 35.06% from the prior year.
- Income from Continuing Operations declined to 3681000.0 in Q1 2026 per ACAD's latest filing, from 46323000.0 in the prior quarter.
- Across five years, Income from Continuing Operations topped out at 169415000.0 in Q4 2024 and bottomed at 113056000.0 in Q1 2022.
- The 5-year median for Income from Continuing Operations is 16600000.0 (2024), against an average of 8379882.35.
- Across the five-year window, Income from Continuing Operations sank 139.62% in 2023 and soared 2897.22% in 2024, its largest moves.
- Year by year, Income from Continuing Operations stood at 41644000.0 in 2022, then surged by 209.77% to 45714000.0 in 2023, then jumped by 270.6% to 169415000.0 in 2024, then slumped by 72.66% to 46323000.0 in 2025, then sank by 92.05% to 3681000.0 in 2026.
- Per Business Quant, the three latest ACAD Income from Continuing Operations figures stand at 3681000.0 (Q1 2026), 46323000.0 (Q4 2025), and 71779000.0 (Q3 2025).
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | -37.09 Mn |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 227.36 Mn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | -3.68 Mn |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 1.03 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 727.20 Mn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | -26.94 Mn |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | 362.00 Mn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | -453.82 Mn |
| 10 | Acadia Pharmaceuticals | 4.23 Bn | 3.38 Bn | 243.27 Mn | 3.68 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 3.68 Mn |
| Dec 31, 2025 | 46.32 Mn |
| Sep 30, 2025 | 71.78 Mn |
| Jun 30, 2025 | 26.66 Mn |
| Mar 31, 2025 | 19.01 Mn |
| Dec 31, 2024 | 169.42 Mn |
| Sep 30, 2024 | 32.76 Mn |
| Jun 30, 2024 | 33.39 Mn |
| Mar 31, 2024 | 16.60 Mn |
| Dec 31, 2023 | 45.71 Mn |
| Sep 30, 2023 | -65.10 Mn |
| Jun 30, 2023 | 1.11 Mn |
| Mar 31, 2023 | -43.00 Mn |
| Dec 31, 2022 | -41.64 Mn |
| Sep 30, 2022 | -27.17 Mn |
| Jun 30, 2022 | -34.01 Mn |
| Mar 31, 2022 | -113.06 Mn |
| Dec 31, 2021 | -46.62 Mn |
| Sep 30, 2021 | -14.46 Mn |
| Jun 30, 2021 | -43.87 Mn |